143 related articles for article (PubMed ID: 16201104)
1. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
3. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
7. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
8. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.
Shiffman ML; Stewart CA; Hofmann CM; Contos MJ; Luketic VA; Sterling RK; Sanyal AJ
J Infect Dis; 2000 Dec; 182(6):1595-601. PubMed ID: 11069229
[TBL] [Abstract][Full Text] [Related]
9. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
Fujiyama S; Tanaka M
Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
[TBL] [Abstract][Full Text] [Related]
11. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
12. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Soga K; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
[TBL] [Abstract][Full Text] [Related]
13. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.
Ikeda K; Saitoh S; Arase Y; Chayama K; Suzuki Y; Kobayashi M; Tsubota A; Nakamura I; Murashima N; Kumada H; Kawanishi M
Hepatology; 1999 Apr; 29(4):1124-30. PubMed ID: 10094956
[TBL] [Abstract][Full Text] [Related]
14. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
[TBL] [Abstract][Full Text] [Related]
15. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
[TBL] [Abstract][Full Text] [Related]
16. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center.
Ikeda K; Arase Y; Saitoh S; Kobayashi M; Someya T; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
Intervirology; 2006; 49(1-2):82-90. PubMed ID: 16166794
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
[TBL] [Abstract][Full Text] [Related]
18. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
Kurosaki M; Matsunaga K; Hirayama I; Tanaka T; Sato M; Komatsu N; Umeda N; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Asahina Y; Miyake S; Enomoto N; Izumi N
J Hepatol; 2008 May; 48(5):736-42. PubMed ID: 18329125
[TBL] [Abstract][Full Text] [Related]
19. Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan.
Iino S
Antivir Ther; 1998; 3(Suppl 3):143-6. PubMed ID: 10726064
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of chronic hepatitis C: results of a large, prospective cohort study.
Niederau C; Lange S; Heintges T; Erhardt A; Buschkamp M; Hürter D; Nawrocki M; Kruska L; Hensel F; Petry W; Häussinger D
Hepatology; 1998 Dec; 28(6):1687-95. PubMed ID: 9828236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
